一线阿法替尼与化疗对EGFR突变伴有脑转移的非小细胞肺癌患者的疗效评价

First-Line Afatinib Versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

1文献来源Schuler M,Wu YL,Hirsh V,et al.First-lineAfatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growthfactor receptor gene mutations and brain metastases[J].J Thorac Oncol,2016,11（3）：380-390.2证据水平2a。3背景EGFR阳性的非小细胞肺癌（non-small celllung cancer,NSCLC）出现脑转移的概率高达44%~63%,但目前极少有针对此类患者的前瞻性临床研究。